Latest publications

Consistency of Response to Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Over 1 Year. Blauvelt A, De Bruin-Weller M, Simpson EL, Chen Z, Ardeleanu M, Rossi AB et al. Dermatol Ther (Heidelb) 2022 Jan; 12(1):9-13

The effectiveness of antibacterial therapeutic clothing based on silver or chitosan as compared with non-antibacterial therapeutic clothing in patients with moderate to severe atopic dermatitis (ABC trial): study protocol for a pragmatic randomized controlled trial. Ragamin A, Fieten KB, Tupker RA, De Wit J, Van Mierlo MMF, Jansen MS et al. Trials 2021 Dec 11; 22(1):902

Dupilumab with Topical Corticosteroids Provides Rapid and Sustained Improvement in Adults with Moderate-to-Severe Atopic Dermatitis Across Anatomic Regions Over 52 Weeks. Blauvelt A, De Bruin-Weller M, Simpson EL, Chen Z, Zhang A, Shumel B et al. Dermatol Ther (Heidelb) 2022 Jan; 12(1):223-231

Efficacy of Dupilumab in Atopic Dermatitis: The Patient's Perspective. De Bruin-Weller M, Merola JF, Hong CH, Baldrich ES, Ettler K, Sierka D et al. Dermatol Ther (Heidelb) 2021 Dec; 11(6):2123-2131

Measurement of IgE to hazelnut allergen components cannot replace hazelnut challenge in Dutch adults. Lyons SA, Welsing PMJ, Hakobyan M, Kansen HM, Knol EF, Otten HG et al. Allergy 2021 Nov 03

Development and validation of the Food Allergy Severity Score. Fernández-Rivas M, Gómez García I, Gonzalo-Fernández A, Fuentes Ferrer M, Dölle-Bierke S, Marco-Martín G et al. Allergy 2021 Oct 30

Dupilumab Treatment Provides Sustained Improvements Over 2 Years in Symptoms and Quality of Life in Adults with Atopic Dermatitis. Yosipovitch G, De Bruin-Weller M, Armstrong A, Wu JJ, Herranz P, Thaçi D et al. Dermatol Ther (Heidelb) 2021 Dec; 11(6):2147-2157

Expert Perspectives on Key Parameters that Impact Interpretation of Randomized Clinical Trials in Moderate-to-Severe Atopic Dermatitis. Silverberg JI, Simpson EL, Armstrong AW, De Bruin-Weller MS, Irvine AD, Reich K et al. Am J Clin Dermatol 2022 Jan; 23(1):1-11

Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: results from five tralokinumab clinical trials. Wollenberg A, Beck LA, De Bruin Weller M, Simpson EL, Imafuku S, Boguniewicz M et al. Br J Dermatol 2021 Oct 12

Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis. Silverberg JI, Simpson EL, Boguniewicz M, De Bruin-Weller MS, Foley P, Kataoka Y et al. Acta Derm Venereol 2021 Nov 10; 101(11):adv00585

Conjunctival inflammation in dupilumab-treated atopic dermatitis comprises a multicellular infiltrate with elevated T1/T17 cytokines: A case series study. Bakker DS, Ter Linde JJM, Amini MM, Ariëns LFM, Van Luijk CM, De Bruin-Weller MS et al. Allergy 2021 Dec; 76(12):3814-3817

Peanut Can Be Used as a Reference Allergen for Hazard Characterization in Food Allergen Risk Management: A Rapid Evidence Assessment and Meta-Analysis. Turner PJ, Patel N, Ballmer-Weber BK, Baumert JL, Blom WM, Brooke-Taylor S et al. J Allergy Clin Immunol Pract 2022 Jan; 10(1):59-70

Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results. Silverberg JI, De Bruin-Weller M, Bieber T, Soong W, Kabashima K, Costanzo A et al. J Allergy Clin Immunol 2021 Aug 14

Rapid and Sustained Effect of Dupilumab on Work Productivity in Patients with Difficult-to-treat Atopic Dermatitis: Results from the Dutch BioDay Registry. Ariëns LFM, Bakker DS, Spekhorst LS, Van der Schaft J, Thijs JL, Haeck I et al. Acta Derm Venereol 2021 Oct 19; 101(10):adv00573

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial. Blauvelt A, Teixeira HD, Simpson EL, Costanzo A, De Bruin-Weller M, Barbarot S et al. JAMA Dermatol 2021 Sep 01; 157(9):1047-1055